UroGen Pharma (URGN) Misses Q4 EPS by 6c
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Join SI Premium – FREE
UroGen Pharma (NASDAQ: URGN) reported Q4 EPS of ($0.54), $0.06 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $37.84 million versus the consensus estimate of $41.45 million.
For earnings history and earnings-related data on UroGen Pharma (URGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- UBS Upgrades SolarEdge (SEDG) to Buy
- ArcBest Corp (ARCB) Reiterated at Market Outperform by Citizens Post 75th ACT Seminar
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
